This page shows the latest Cancer Drugs Fund news and features for those working in and with pharma, biotech and healthcare.
HR+, HER2-, node-positive early-stage breast cancer at high-risk of recurrence. ... The availability of the combination treatment on the NHS is supported by interim funding from the Cancer Drugs Fund until routine NHS baseline funding is established.
A new fund, the Innovative Medicines Fund (IMF), has been established and will operate in the same way as the existing Cancer Drugs Fund (CDF), which can fast-track cutting-edge ... Scotland has already established a similar fund for innovative treatments
Diagnoses of non-melanoma skin cancer are increasing and have been forecast to continue until 2040. ... NICE first recommended that Libtayo should be made available through the Cancer Drugs Fund (CDF) in 2019.
Lung cancer is the cancer with the highest mortality rate and accounts for more than one in five (21%) of all deaths caused by cancer. ... Imfinzi was made available as a treatment option for these patients via the Cancer Drugs Fund (CDF) – a scheme
The National Institute for Health and Care Excellence (NICE) has issued a final appraisal document recommending Amgen’s Lumykras (sotorasib) for treatment use within the Cancer Drugs Fund. ... The treatment will now be available to eligible patients in
Of those whose cancer has advance, around 22% will need second-line therapy. ... The treatment will move from interim funding – via the Cancer Drugs Fund (CDF) – to routine funding in second line therapy.
More from news
Approximately 56 fully matching, plus 128 partially matching documents found.
A very notable victory has just been announced, with Keytruda becoming the first of the groundbreaking immunotherapy drugs to exit the Cancer Drugs Fund and secure NICE approval for first-line ... Current projects include developing antibodies for use as
Companies have seen repeated attempts by the Government and NHS England to prevent patients from accessing new medicines, from the controversial reforms to the Cancer Drugs Fund to the ‘run rate’
In this PME market access supplement we look at the direction of travel in France and Germany and there’s an introduction to the UK’s new-look Cancer Drugs Fund.
products. In the UK, for instance, NICE now regulates access to the Cancer Drugs Fund, and products will need to meet NICE thresholds in order to be reimbursed.
Health stakeholders should focus not on the cost of drugs but on the value they provide. ... Proposed changes to the Cancer Drugs Fund in England include provision for access at a provisional price that is considered potentially cost-effective.
More from intelligence
Approximately 2 fully matching, plus 12 partially matching documents found.
Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around ... the uptake of new drugs and med tech, and the
This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
From the Cancer Drugs Fund to the promised Innovation Drugs Fund, initiatives have been created as technical ‘work-arounds’ for NICE and for an HTA system that has not kept pace
So, it is essential to understand the roles of local organisations, such as Primary Care Networks (PCNs) and Cancer Alliances and Rapid Diagnostic Centres (RDCs). ... This may include some elements of commissioning alongside the Cancer Drugs Fund and the
topical healthcare issues including NICE, the Cancer Drugs Fund, biosimilars, the impact of Digital on pharma and the NHS in general.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...